Pharmaceutical

Runimotamab by Genentech USA for Solid Tumor: Likelihood of Approval

Runimotamab is under clinical development by Genentech USA and currently in Phase I for Solid Tumor.

Dec 22, 2023 - 18:00
Runimotamab is under clinical development by Genentech USA and currently in Phase I for Solid Tumor.
Read the original article

Tags:

Previous Article

Volrustomig by AstraZeneca for Cervical Cancer: Likelihood of Approval

Next Article

IDE-161 by Ideaya Biosciences for Metastatic Ovarian Cancer: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Legal challenges put off label use of gender affirming care drugs in jeopardy

Legal challenges put off label use of gender affirming ...

Mar 19, 2023

Johnson & Johnson agrees to acquire Ambrx Biopharma for $2bn

Johnson & Johnson agrees to acquire Ambrx Biopharma for...

Jan 9, 2024

Biden nominates Monica Bertagnolli to head NIH

Biden nominates Monica Bertagnolli to head NIH

May 15, 2023